Moreover, FAT10 limits the efficacy of anti-VEGF therapy for hepatocellular carcinoma by simultaneously stabilising multiple proteins, including HIF1α, β-catenin, STAT3, and TAB3 proteins [33]. This evidence concerns the gene HIF1A and hepatocellular carcinoma.